Douglas L. Arnold
Artificial Intelligence · 2008–2018
A researcher in the Science corpus: 8 papers; trusts 10 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Artificial Intelligence — 12 citations into it
- Computer Vision and Pattern Recognition — 11 citations into it
- Radiology, Nuclear Medicine and Imaging — 9 citations into it; #2,948 of 3,265 by trust here, #2,400 by citations
Whom Douglas L. Arnold trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Yarin Gal
- Alex Kendall
- Stephen M. Smith
- Alex Krizhevsky
- Geoffrey E. Hinton
- Yoshua Bengio
- Zoubin Ghahramani
Who trusts Douglas L. Arnold overall
Papers from Douglas L. Arnold's perspective
Ordered by how strongly the researchers Douglas L. Arnold trusts endorse each paper. Same corpus, a different order for every researcher.
- ImageNet classification with deep convolutional neural networks
- Learning Multiple Layers of Features from Tiny Images
- ImageNet Large Scale Visual Recognition Challenge
- Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift (International Conference on Machine Learning)
- Deep Residual Learning for Image Recognition (Computer Vision and Pattern Recognition)
- Adam: A Method for Stochastic Optimization (International Conference on Learning Representations)
- Gradient-based learning applied to document recognition
- ImageNet: A large-scale hierarchical image database
- Long Short-Term Memory
- Attention is All you Need (Neural Information Processing Systems)
Their papers
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. (2018) — 796 citations
- Exploring Uncertainty Measures in Deep Networks for Multiple Sclerosis Lesion Detection and Segmentation (2018) — 510 citations
- Using Deep Learning Algorithms to Automatically Identify the Brain MRI Contrast: Implications for Managing Large Databases (2018) — 28 citations
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) — 1,605 citations
- Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) — 1,645 citations
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. (2012) — 1,153 citations
- Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) — 1,653 citations
- B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) — 1,321 citations